For instance, a study using DLBCL cell lines showed a synergetic effect of a combination of EZH2 inhibitor and decitabine, which is a DNMT inhibitor, on the expression of class I MHCs [31]. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.